NCT02228096已完成2 期
A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 75
- 试验地点
- 26
- 主要终点
- Overall Remission Rate (ORR) Per Independent Review Committee (IRC) (for ALL Participants)
研究概览
简要总结
This was a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of an experimental therapy called CTL019 T-cells in pediatric patients with B-cell acute lymphoblastic leukemia, who were refractory to standard chemotherapy regimen or relapsed after allogeneic stem cell transplant.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 3 Years 至 21 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Relapsed or refractory pediatric B-cell ALL and lymphoblastic lymphoma:
- •2nd or greater Bone Marrow (BM) relapse OR
- •Any BM relapse after allogeneic SCT and must be > 6 months from SCT at the time of CTL019 infusion OR
- •Refractory as defined by not achieving a CR after 2 cycles of a standard chemotherapy regimen chemotherapy regimen or chemorefractory as defined by not achieving a CR after 1 cycle of standard chemotherapy for relapse leukemia OR
- •Patients with Philadelphia chromosome positive (Ph+) ALL are eligible if they are intolerant to or have failed 2 lines of tyrosine kinase inhibitor therapy (TKI), or if TKI therapy is contraindicated OR
- •Ineligible for allogeneic SCT
- •For relapsed patients, CD19 tumor expression demonstrated in bone marrow or peripheral blood by flow cytometry within 3 months of study entry
- •Adequate organ function defined as:
- •Renal function defined as (Calculated creatinine clearance or radioisotope Glomerular Filtration Rate (GFR) > 60 mL/min/1.73 m2 OR serum creatinine based on age/gender
- •Alanine Aminotransferase (ALT) <= 5 times the upper limit of normal (ULN) for age;
- •Bilirubin < 2.0 mg/dL;
- •Must have a minimum level of pulmonary reserve defined as ≤Grade 1 dyspnea and pulse oxygenation > 91% on room air
- •Left Ventricular Shortening Fraction (LVSF) ≥ 28% confirmed by echocardiogram, or Left Ventricular Ejection Fraction (LVEF) ≥ 45% confirmed by echocardiogram or MUGA within 7 days of screening
- •Bone marrow with ≥ 5% lymphoblasts by morphologic assessment at screening
- •Life expectancy > 12 weeks
- •Age 3 at the time of screening per protocol to age 21 at the time of initial diagnosis
- •Karnofsky (age ≥ 16 years) or Lansky (age < 16 years) performance status ≥ 50 at screening
- •Signed written informed consent and assent forms (if applicable) must be obtained prior to any study procedures
- •Once all other eligibility criteria are confirmed, must have an apheresis product of non-mobilized cells received and accepted by the manufacturing site. Note: Apheresis product will not be shipped to or assessed for acceptance by the manufacturing site until documented confirmation of all other eligibility criteria is received.
- •Patients with active CNS leukemia involvement defined as CNS-3 by CSF findings only are eligible but will have their CTL019 infusion delayed until CNS disease is reduced to CNS-1 or CNS-2 by CSF findings. Patients with other forms of active CNS-3 leukemic involvement such as CNS parenchymal or ocular disease, cranial nerve involvement or significant leptomeningeal disease are not eligible. However, such patients with other forms of CNS-3 leukemic involvement (non-CSF involvement) are eligible if there is documented evidence of disease stabilization for at least 3 months prior to CTL019 infusion. Patients must have no acute/ongoing neurologic toxicity > Grade 1 with the exception of a history of controlled seizures or fixed neurologic deficits that have been stable/improving over the past 3 months.
排除标准
- •Isolated extra-medullary disease relapse
- •Patients with concomitant genetic syndrome: such as patients with Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome. Patients with Down Syndrome will not be excluded.
- •Patients with Burkitt's lymphoma/leukemia (i.e. patients with mature B-cell ALL, leukemia with B-cell [surface Immunoglobulin (sIg) positive and kappa or lambda restricted positivity] ALL, with FAB L3 morphology and /or a MYC translocation)
- •Prior malignancy, except carcinoma in situ of the skin or cervix treated with curative intent and with no evidence of active disease
- •Prior treatment with gene therapy product
- •Treatment with any prior anti-CD19/anti-CD3 therapy, or any other anti-CD19 therapy
- •Presence of Grade 2 to 4 acute or extensive chronic graft-versus-host disease (GVHD)
- •Patient has participated in an investigational research study using an investigational agent within the last 30 days prior to screening
- •Pregnant or nursing (lactating) women. NOTE: female study participants of reproductive potential must have a negative serum or urine pregnancy test performed within 48 hours before infusion
- •Active or latent hepatitis B or active hepatitis C (test within 8 weeks of screening), or any uncontrolled infection at screening
- •HIV positive test within 8 weeks of screening
- •The following medications are excluded:
- •Steroids: Therapeutic systemic doses of steroids must be stopped > 72 hours prior to CTL019 infusion. However, the following physiological replacement doses of steroids are allowed: < 12 mg/m2/day hydrocortisone or equivalent
- •Allogeneic cellular therapy: Any donor lymphocyte infusions (DLI) must be completed > 6 weeks prior to CTL019 infusion
- •GVHD therapies: Any systemic drug used for GVHD must be stopped > 4 weeks prior to CTL019 infusion to confirm that GVHD recurrence is not observed (e.g. calcineurin inhibitors, methotrexate or other chemotherapy drugs, mycophenolate, rapamycin, thalidomide, or immunosuppressive antibodies such as anti-CD20 (rituximab), anti-tumor necrosis factor [anti-TNF], anti-interleukin 6 [anti-IL6] or anti-interleukin 6 receptor [anti-IL6R], systemic steroids)
- •Chemotherapy:
- •Tyrosine kinase inhibitors and hydroxyurea must be stopped > 72 hours prior to CTL019 infusion
- •The following drugs must be stopped > 1 week prior to CTL019 infusion and should not be administered concomitantly or following lymphodepleting chemotherapy: vincristine, 6-mercaptopurine, 6-thioguanine, methotrexate < 25 mg/m2, cytosine arabinoside < 100 mg/m2/day, asparaginase (non-pegylated)
- •The following drugs must be stopped >2 weeks prior to CTL019 infusion: salvage chemotherapy (e.g. clofarabine, cytosine arabinoside > 100 mg/m2, anthracyclines, cyclophosphamide, methotrexate ≥ 25 mg/m2), excluding the required lymphodepleting chemotherapy drugs
- •Pegylated-asparaginase must be stopped > 4 weeks prior to CTL019 infusion e. CNS disease prophylaxis:
- •CNS prophylaxis treatment must be stopped > 1 week prior to CTL019 infusion (e.g. intrathecal methotrexate) f. Radiotherapy:
- •Non-CNS site of radiation must be completed > 2 weeks prior to CTL019 infusion
- •CNS directed radiation must be completed > 8 weeks prior to CTL019 infusion g. Anti T-cell Antibodies: Administration of any T cell lytic or toxic antibody (e.g. alemtuzumab) within 8 weeks prior to CTL019 is prohibited since residual lytic levels may destroy the infused CTL019 cells and/or prevent their in vivo expansion. If such an agent has been administered within 8 weeks prior to CTL019, contact the Sponsor, consider consultation with an pharmacology expert, and consider measuring residual drug levels, if feasible, prior to CTL019 infusion Women of child-bearing potential (defined as all women physiologically capable of becoming pregnant) and all male participants, unless they are using highly effective methods of contraception for a period of 1 year after the CTL019 infusion. Highly effective contraception methods include:
- •Total abstinence (when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are NOT acceptable methods of contraception
- •Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment
- •Male sterilization (at least 6 months prior to screening). For female patients on the study the vasectomized male partner should be the sole partner for that patient
- •Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception
- •Use of IUDs are excluded due to increased risks of infection and bleeding in this population. However, IUD inserted prior to consent may remain in place, and a second method of contraception is mandated
- •In case of use of oral contraception, women must be stable on the same pill for a minimum of 3 months before taking study treatment.
- •Women who are not of reproductive potential (defined as either <11 years of age, Tanner Stage 1, post-menopausal for at least 24 consecutive months (i.e. have had no menses) or have undergone hysterectomy, bilateral salpingectomy, and/or bilateral oophorectomy) are eligible without requiring the use of contraception. Women who are not yet of reproductive potential are to agree to use acceptable forms of contraception when they reach reproductive potential if within 1 year of CTL019 or if CAR cells are present in the blood by PCR. Acceptable documentation includes written or oral documentation communicated by clinician or clinician's staff of one of the following:
- •Demographics show age < 11
- •Physical examination indicates Tanner Stage 1
- •Physician report/letter
- •Operative report or other source documentation in the patient record
- •Discharge summary
- •Follicle stimulating hormone measurement elevated into the menopausal range
结局指标
主要结局
Overall Remission Rate (ORR) Per Independent Review Committee (IRC) (for ALL Participants)
时间窗: within 6 months after CTL019 infusion
ORR is defined as the percentage of participants with a best overall disease response of complete remission (CR) or Complete remission with incomplete blood count recovery (CRi), where the best overall disease response is defined as the best disease response recorded from CTL019 infusion until the start of new anticancer therapy. Best response was assigned in the following order: CR, CRi, CR or CRi with residual mediastinal disease, No response and Unknown.
Overall Remission Rate (ORR) Per Local Investigator Assessment (for Lymphoblastic Lymphoma Patients Only)
时间窗: 6 months after CTL019
Overall Remission Rate (ORR), which includes Complete Remission (CR) and Complete Remission with Incomplete Blood Count Recovery (CRi), as determined by assessments of peripheral blood, bone marrow, CNS symptoms, physical exam (PE) and cerebrospinal fluid (CSF). This primary endpoint was based on the local investigator assessment. No participants with lymphoblastic lymphoma were infused in this study.
次要结局
- Percentage of Subjects Who Achieved CR or CRi and Then Proceeded to SCT While in Remission Prior to Month 6 Response - Per IRC Assessment(prior to Month 6)
- Relapse-free Survival (RFS) for Responders Per Local and IRC Assessment(60 Months)
- Percentage of Participants With CR or CRi With Minimum Residual Disease (MRD) Negative Bone Marrow 6 Months After CTL019 Infusion(within 6 months)
- ORR by Low Baseline Bone Marrow Burden Within 6 Months Post CTL019 Infusion(Within 6 months)
- Bone Marrow MRD Status by Flow Cytometry Within 6 Months Post CTL019 Infusion by Baseline Extramedullary Disease Presence: Yes(Within 6 months)
- Duration of Remission (DoR) Censoring HSCT by High Baseline Bone Marrow Tumor Burden(Within 6 months)
- Peripheral Blood PK Parameters for Tisagenlecleucel Transgene Levels by qPCR, by Day 28 Disease Response by Local & IRC Assessment: Tmax(Day 28)
- Key Inflammatory Markers and Cytokine Parameters in Blood Within 1 Month by Maximum Cytokine Release Syndrome (CRS) Grade: INF-gamma(Pre-infusion, Baseline, Day 7, Day 14, Day 21, Day 28, Month 3)
- Key Inflammatory Markers and Cytokine Parameters in Blood Within 1 Month by Maximum Cytokine Release Syndrome (CRS) Grade: Interleukin-6 (IL-6)(Pre-infusion, Baseline, Day 7, Day 14, Day 21, Day 28, Month 3)
- Duration of Remission (DOR) Per Local and IRC Assessment(From CR or CRi to relapse or death up to 60 months)
- Overall Survival (OS)(60 Months)
- Percentage of Participants With Clinical Response Without Stem Cell Transplantation (SCT) at Month 6 - Per IRC Assessment(Month 6)
- Humoral Immunogenicity Interpretation by Day 28 Disease Response Per IRC (Anti-CTL019 Antibodies)(Baseline; Day 14; Day 28; Month 3; Month 6; Month 12; Month 24, Month 36)
- Bone Marrow MRD Status by Flow Cytometry Within 6 Months Post CTL019 Infusion by Baseline Extramedullary Disease Presence: No(Within 6 months)
- Duration of Remission (DoR) Censoring Hematopoietic Stem Cell Transplantation (HSCT) by Low Baseline Bone Marrow Tumor Burden(Within 6 months)
- Participants Achieving Cellular Immunogenicity Net Response by Day 28 Response Per IRC(Baseline; Day 14; Day 28; Month 3; Month 6; Month 12; Month 24, Month 36)
- Peripheral Blood PK Parameters for Tisagenlecleucel Transgene Levels by qPCR, by Day 28 Disease Response by Local & IRC Assessment: AUC0-28d and AUC0-84d(0 - 28 days post-infusion for AUC0-28d and 0 - 84 days post-infusion for AUC0-84d)
- CD19 Status of Bone Marrow/Blood Relapse in FAS Patients Who Achieved CR or CRi and Then Relapsed(At time of relapse up to 60 months)
- Event-free Survival (EFS) Per Local and IRC Assessment(60 Months)
- Secondary Outcome: Percentage of Participants Attaining CR or CRi With MRD Negative Bone Marrow Status at Day 28 +/- 4 Days After CTL019 Infusion(Day 28)
- ORR by High Baseline Bone Marrow Burden Within 6 Months Post CTL019 Infusion(Within 6 months)
- Duration of Remission (DoR) Censoring HSCT by Baseline Extramedullary Disease Presence: No(Within 6 months)
- Key Inflammatory Markers and Cytokine Parameters in Blood Within 1 Month by Maximum Cytokine Release Syndrome (CRS) Grade: C Reactive Protein (CRP)(Pre-infusion, Baseline, Day 7, Day 14, Day 21, Day 28, Month 3)
- CTL019 Transgene Levels by qPCR CTL019 Cells by in qPCR Blood and Bone Marrow(Enrollment; D1; D4; D7; D11; D14; D21; D28; M3; M6; M9, M12; M18; M24, M30, M36, M42, M48 for transgene levels in blood; Screening, D28, M3, M6 for transgene levels in bone marrow)
- ORR by Baseline Extramedullary Disease Presence of Yes Within 6 Months Post CTL019 Infusion(Within 6 months)
- Duration of Remission (DoR) Censoring HSCT by Baseline Extramedullary Disease Presence: Yes(Within 6 months)
- Peripheral Blood PK Parameters for Tisagenlecleucel Transgene Levels by qPCR, by Day 28 Disease Response by Local & IRC Assessment: Cmax(Day 28)
- Peripheral Blood PK Parameters for Tisagenlecleucel Transgene Levels by qPCR, by Day 28 Disease Response by Local & IRC Assessment: Clast(Day 28)
- Peripheral Blood PK Parameters for Tisagenlecleucel Transgene Levels by qPCR, by Day 28 Disease Response by Local & IRC Assessment: Tlast(Day 28)
- ORR by Baseline Extramedullary Disease Presence of No Within 6 Months Post CTL019 Infusion(Within 6 months)
- Bone Marrow (BM) Minimum Residual Disease (MRD) Status by Flow Cytometry Within 6 Months Post CTL019 Infusion by High Baseline Bone Marrow Tumor Burden(Within 6 months)
- Bone Marrow MRD Status Was by Flow Cytometry Within 6 Months Post CTL019 Infusion by Low Baseline Bone Marrow Tumor Burden(Within 6 months)
- Peripheral Blood PK Parameters for Tisagenlecleucel Transgene Levels by qPCR, by Day 28 Disease Response by Local & IRC Assessment: T1/2(Day 28)
- Percentage of CD19+ B Cell Levels in Peripheral Blood by Day 28 Disease Response by IRC Assessment(Enrollment/Pre-Chemotherapy; Pre-infusion; Baseline; Day 7; Day 14; Day 21; Day 28; Month 3; Month 6; Month 9; Month 12; Month 24; Month 36)
- Site of Initial Relapse Among FAS Patients Who Achieved CR/CRi and Then Relapsed(At time of relapse up to 60 months)
- Time to B-cell Recovery in Participants Who Achieved CR or CRi by IRC(during the whole study, up to 60 months)
- Key Inflammatory Markers and Cytokine Parameters in Blood Within 1 Month by Maximum Cytokine Release Syndrome (CRS) Grade: Ferritin(Pre-infusion, Baseline, Day 7, Day 14, Day 21, Day 28, Month 3)
- Key Inflammatory Markers and Cytokine Parameters in Blood Within 1 Month by Maximum Cytokine Release Syndrome (CRS) Grade: Interleukin-2 (IL-2)(Pre-infusion, Baseline, Day 7, Day 14, Day 21, Day 28, Month 3)
研究者
研究点 (26)
Loading locations...
相似试验
撤回
2 期
Study of Efficacy and Safety of CTL019 in Adult ALL PatientsB-cell Acute Lymphoblastic LeukemiaRelapsed B-cell Acute Lymphoblastic LeukemiaRefractory B-cell Acute Lymphoblastic LeukemiaNCT02167360Abramson Cancer Center at Penn Medicine
已完成
2 期
Study of Efficacy and Safety of CTL019 in Pediatric ALL PatientsB-cell Acute Lymphoblastic LeukemiaNCT02435849Novartis Pharmaceuticals80
已完成
2 期
LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.Non-Small-Cell Lung CancerNCT02450903Novartis Pharmaceuticals20
尚未招募
2 期
A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLCALK-positive NSCLCNCT05482087Xuanzhu Biopharmaceutical Co., Ltd.190
招募中
2 期
A Study of KC1036 in Patients with Advanced Thymic TumorsThymic TumorsNCT05683886Beijing Konruns Pharmaceutical Co., Ltd.30